Health Affairs March 24, 2023
William Walters, Richard Hughes IV

Recent cuts to the price of insulin raise this question: Why should those who rely on insulin for survival pay anything out-of-pocket to acquire it?

In a surprising move at the beginning of March, Eli Lilly, the manufacturer of Humalog, cut insulin prices by 70 percent and capped patient out-of-pocket costs at $35 per month, mirroring an out-of-pocket price cap for Medicare Part D beneficiaries recently implemented as a part of the The Inflation Reduction Act (IRA). Eli Lilly’s price cap, however, extends to all patients, not just those covered by Medicare Part D prescription drug plans.

Eli Lilly’s actions are not just laudable; for type 1 diabetics, they are potentially lifesaving. A steady stream of news stories documenting the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Patient / Consumer, Pharma, Pharma / Biotech
CMS extends special enrollment period for persons no longer eligible for Medicaid, CHIP
The Ripple Effect: Ways to Make Health in All Policies Stick in Kansas and Beyond to Enhance Health and Equity
Katie Couric Talks Colon Cancer, Health Equity And AI
Finger on the Pulse: The State of Primary Care in the U.S. and Nine Other Countries
Can Google Street View data provide heart health insights?

Share This Article